Second-quarter sales of cholesterol drug Repatha rose ... from a previous low end forecast of $32.5 billion. Amgen narrowed its 2024 adjusted earnings estimate and now expects a profit of $19. ...

Amgen AMGN reported third-quarter 2024 adjusted ... pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024, recorded sales of $36 million in the third quarter compared with $12 million ...

Amgen has announced a total revenue of $8.5bn in Q3 2024, a 23% increase from a $6.9bn revenue in the same quarter of last year. The growth is driven by increased product sales by 24%, which ...

Amgen Inc (NASDAQ:AMGN) reported a 19% year-over-year increase in total revenues for 2024, driven by strong product sales growth. The company achieved double-digit growth for 10 products and had ...

In particular, management highlighted growth in Repatha and Evenity, which delivered 45% and 36% growth even as they have reached 2024 sales of $2.22B and $1.56B respectively. Among Amgen's top ...

Aug. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN ... to $8.4 billion in comparison to the second quarter of 2023. Product sales grew 20%, driven by 26% volume growth, partially offset by 3% ...

Oct 30 (Reuters) - Amgen (AMGN.O), opens new tab reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and osteoporosis, and said mid-stage ...

Biosimilars also performed well, with a 9% sales increase. Amgen Inc. (NASDAQ:AMGN) returned capital to shareholders with a 6% increase in its dividend, paying $2.25 per share in Q2. For 2024 ...

Amgen discovers, develops ... (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics ...

Oct. 25, 2024 /PRNewswire/ -- Amgen (AMGN) today announced that its ... (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc ...